Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 pharmacokinetics in healthy Chinese subjects
NCT05633862Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nerandomilast (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 144 hours and Maximum Measured Concentration of BI 1015550 in Plasma at 144 hours. Started Jan 2023; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT05633862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633862.